| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.23 | 0.0004 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0006 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0007 |
| mRNA | MST-312 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0007 |
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0007 |
| mRNA | WP1130 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0007 |
| mRNA | nakiterpiosin | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0008 |
| mRNA | 17-AAG | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0009 |
| mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0009 |